Managing Waldenström's macroglobulinemia with BTK inhibitors

Bruton's tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed/refractory Waldenström's macroglobulinemia (WM) and for patients with WM who are unsuitable for immunochemotherapy (ICT). It offers deep and durable responses with a manageable safety pro...

Full description

Saved in:

Bibliographic Details
Published in:	Leukemia Vol. 37; no. 1; pp. 35 - 46
Main Authors:	Buske, Christian, Jurczak, Wojciech, Salem, Joe-Elie, Dimopoulos, Meletios A
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.01.2023
Subjects:	Agammaglobulinaemia Tyrosine Kinase Atrial Fibrillation - chemically induced Atrial Fibrillation - drug therapy Bruton's tyrosine kinase Cardiovascular diseases Chemotherapy Clinical trials Covalence CXCR4 protein Effectiveness Health risks Humans Immunotherapy Inhibitor drugs Kinases Macroglobulinemia Mutation MyD88 protein Myeloid Differentiation Factor 88 - genetics Neoplasm Recurrence, Local - drug therapy Patients Protein Kinase Inhibitors - pharmacology Protein-tyrosine kinase Risk management Safety management Selectivity Side effects Signal Transduction Toxicity Tyrosine Waldenstrom Macroglobulinemia - drug therapy Waldenstrom Macroglobulinemia - genetics
ISSN:	0887-6924, 1476-5551, 1476-5551
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!